|
Trial location
|
|
Sub-Saharan countries only
|
104 (85.9)
|
|
• South Africa
|
20 (19.2)
|
|
• Nigeria
|
12 (11.5)
|
|
• Tanzania
|
10 (9.6)
|
|
• Kenya
|
8 (7.6)
|
|
• Uganda
|
8 (7.6)
|
|
• Malawi
|
6 (5.7)
|
|
• Rwanda
|
4 (3.8)
|
|
• Ethiopia
|
3 (2.8)
|
|
Several Sub-Saharan countries
|
5 (4.1)
|
|
Sub-Saharan African countries and high-income countries (HICs) or other countries (not HICs)
|
12 (8.9)
|
|
Medical area
|
|
Malaria
|
25 (20.6)
|
|
HIV/AIDS
|
24 (19.9)
|
|
Tuberculosis
|
4 (3.3)
|
|
Diarrheal diseases
|
3 (2.4)
|
|
Preterm birth complications
|
2 (1.6)
|
|
Other diseases
|
63 (52.2)
|
|
Study design
|
|
Parallel groups
|
97 (80.1)
|
|
Clusters
|
19 (15.8)
|
|
Factorial design
|
3 (2.4)
|
|
Cross-over
|
2 (1.7)
|
|
Experimental intervention
|
|
Pharmacological (drugs and nutritional supplements)
|
74 (61.1)
|
|
Nonpharmacological
|
47 (38.9)
|
|
• Participative interventions
|
40 (85.1)
|
|
• Devices
|
3 (6.3)
|
|
• Surgical procedures
|
1 (2.3)
|
|
• Therapeutic strategies
|
3 (6.3)
|
|
Comparator
|
|
Active treatment
|
43 (35.5)
|
|
Usual care
|
32 (26.4)
|
|
Placebo
|
24 (19.9)
|
|
Other
|
22 (18.2)
|
|
Sample size (median [IQR])
|
346 [160–932]
|
